Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        41-50 of 63 results

        Refine search

        Research

        Comparison of group A streptococcal titres in healthy children and those with pharyngitis and skin infections

        Rates of acute rheumatic fever, a sequelae of group A Streptococcal (GAS) infection, remain unacceptably high in Indigenous Māori and Pacific children in New Zealand. This prospective study aimed to describe GAS antibody titres in healthy children (5–14 years) by ethnicity, and to determine how paired titres vary with GAS culture positive and negative pharyngitis, and GAS skin infections. ...

        News & Events

        Urgent action needed to stop 500 preventable deaths

        A new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken. ...

        Research

        Protocol for the systematic review of the epidemiology of superficial Streptococcal A infections (skin and throat) in Australia

        We have produced a protocol for the comprehensive systematic review of the current literature around superficial group A Streptococcal infections in Australia. ...

        Research

        Time to address the neglected burden of group A Streptococcus

        Jonathan Carapetis AM JR AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@ ...

        Research

        Distinct Streptococcus pneumoniae cause invasive disease in Papua New Guinea

        Streptococcus pneumoniae is a key contributor to childhood morbidity and mortality in Papua New Guinea (PNG). For the first time, whole genome sequencing of 174 isolates has enabled detailed characterisation of diverse S. pneumoniae causing invasive disease in young children in PNG, 1989-2014. ...

        Research

        A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

        Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13.  ...

        Research

        Correlates of immunity to Group A Streptococcus: a pathway to vaccine development

        Understanding immunity in humans to Group A Streptococcus (Strep A) is critical for the development of successful vaccines to prevent the morbidity and mortality attributed to Strep A infections. Despite decades of effort, no licensed vaccine against Strep A exists and immune correlates of protection are lacking; a major impediment to vaccine development. ...

        Research

        Streptolysins are the primary inflammasome activators in macrophages during Streptococcus pyogenes infection

        Group A Streptococcus (GAS) is a Gram-positive bacterial pathogen that causes an array of infectious diseases in humans. Accumulating clinical evidence suggests that proinflammatory interleukin (IL)-1beta signaling plays an important role in GAS disease progression. ...

        Research

        Look Who's Talking: Host and Pathogen Drivers of Staphylococcus epidermidis Virulence in Neonatal Sepsis

        Preterm infants are at increased risk for invasive neonatal bacterial infections. S. epidermidis, a ubiquitous skin commensal, is a major cause of late-onset neonatal sepsis, particularly in high-resource settings. The vulnerability of preterm infants to serious bacterial infections is commonly attributed to their distinct and developing immune system. ...

        Research

        An eight-plex immunoassay for Group A streptococcus serology and vaccine development

        Group A Streptococcus (GAS) is a major human pathogen responsible for superficial infections through to life-threatening invasive disease and the autoimmune sequelae acute rheumatic fever (ARF). Despite a significant global economic and health burden, there is no licensed vaccine available to prevent GAS disease. Several pre-clinical vaccines that target conserved GAS antigens are in development. ...

        Page 5 of 7